View Item 

Show simple item record

Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocolpherol, beta‐carotene cancer prevention (ATBC) study
dc.contributor.authorMondul, Alison M.en_US
dc.contributor.authorMoore, Steven C.en_US
dc.contributor.authorWeinstein, Stephanie J.en_US
dc.contributor.authorKaroly, Edward D.en_US
dc.contributor.authorSampson, Joshua N.en_US
dc.contributor.authorAlbanes, Demetriusen_US
dc.date.accessioned2015-09-01T19:30:11Z
dc.date.available2017-01-03T16:21:16Zen
dc.date.issued2015-11-01en_US
dc.identifier.citationMondul, Alison M.; Moore, Steven C.; Weinstein, Stephanie J.; Karoly, Edward D.; Sampson, Joshua N.; Albanes, Demetrius (2015). "Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocolpherol, beta‐carotene cancer prevention (ATBC) study." International Journal of Cancer 137(9): 2124-2132.en_US
dc.identifier.issn0020-7136en_US
dc.identifier.issn1097-0215en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/113106
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherbiomarkersen_US
dc.subject.otherthyroxineen_US
dc.subject.otherTMAOen_US
dc.subject.otherTCA cycleen_US
dc.subject.otherenergy metabolismen_US
dc.subject.otherserologyen_US
dc.subject.otherprostate canceren_US
dc.subject.othermetabolomicsen_US
dc.subject.otherWarburgen_US
dc.subject.otherlipid metabolismen_US
dc.titleMetabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocolpherol, beta‐carotene cancer prevention (ATBC) studyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/113106/1/ijc29576.pdf
dc.identifier.doi10.1002/ijc.29576en_US
dc.identifier.sourceInternational Journal of Canceren_US
dc.identifier.citedreferenceWang XZ, Wang B, Gao ZQ, et al. 1H‐MRSI of prostate cancer: The relationship between metabolite ratio and tumor proliferation. Eur J Radiol 2010; 73: 345 – 51.en_US
dc.identifier.citedreferenceNomura DK, Long JZ, Niessen S, et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010; 140: 49 – 61.en_US
dc.identifier.citedreferenceSantos CR, Schulze A. Lipid metabolism in cancer. FEBS J 2012; 279: 2610 – 23.en_US
dc.identifier.citedreferenceCarracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 2013; 13: 227 – 32.en_US
dc.identifier.citedreferenceHuang C, Freter C. Lipid metabolism, apoptosis and cancer therapy. Int J Mol Sci 2015; 16: 924 – 49.en_US
dc.identifier.citedreferenceWarburg O. On the origin of cancer cells. Science 1956; 123: 309 – 14.en_US
dc.identifier.citedreferenceCostello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005; 5: 143 – 53.en_US
dc.identifier.citedreferenceNomura DK, Lombardi DP, Chang JW, et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 2011; 18: 846 – 56.en_US
dc.identifier.citedreferenceIto K, Suda T. Metabolic requirements for the maintenance of self‐renewing stem cells. Nat Rev Mol Cell Biol 2014; 15: 243 – 56.en_US
dc.identifier.citedreferenceSchlaepfer IR, Rider L, Rodrigues LU, et al Lipid catabolism via cpt1 as a therapeutic target for prostate cancer. Mol Cancer Ther 2014; 13: 2361 – 71.en_US
dc.identifier.citedreferenceFreeman MR, Cinar B, Lu ML. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005; 16: 273 – 9.en_US
dc.identifier.citedreferenceMenendez JA. Fine‐tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta 2010; 1801: 381 – 91.en_US
dc.identifier.citedreferenceTsui MM, York JD. Roles of inositol phosphates and inositol pyrophosphates in development, cell signaling and nuclear processes. Adv Enzyme Regul 2010; 50: 324 – 37.en_US
dc.identifier.citedreferenceScott SA, Mathews TP, Ivanova PT, et al. Chemical modulation of glycerolipid signaling and metabolic pathways. Biochim Biophys Acta 2014; 1841: 1060 – 84.en_US
dc.identifier.citedreferenceCinar B, Mukhopadhyay NK, Meng G, et al. Phosphoinositide 3‐kinase‐independent non‐genomic signals transit from the androgen receptor to akt1 in membrane raft microdomains. J Biol Chem 2007; 282: 29584 – 93.en_US
dc.identifier.citedreferenceCostello LC, Franklin RB. The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000; 59: 269 – 82.en_US
dc.identifier.citedreferenceRiches SF, Payne GS, Morgan VA, et al. Multivariate modelling of prostate cancer combining magnetic resonance derived t2, diffusion, dynamic contrast‐enhanced and spectroscopic parameters. Eur Radiol 2015; 25: 1247 – 1256.en_US
dc.identifier.citedreferenceMullen AR, Hu Z, Shi X, et al. Oxidation of alpha‐ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep 2014; 7: 1679 – 90.en_US
dc.identifier.citedreferenceThomas MA, Nagarajan R, Huda A, et al. Multidimensional mr spectroscopic imaging of prostate cancer in vivo. NMR Biomed 2014; 27: 53 – 66.en_US
dc.identifier.citedreferenceKoeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L‐carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576 – 85.en_US
dc.identifier.citedreferenceBae S, Ulrich CM, Neuhouser ML, et al. Plasma choline metabolites and colorectal cancer risk in the women's health initiative observational study. Cancer Res 2014; 74: 7442 – 52.en_US
dc.identifier.citedreferenceMondul AM, Weinstein SJ, Bosworth T, et al. Circulating thyroxine, thyroid‐stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoS One 2012; 7: e47730en_US
dc.identifier.citedreferenceCross AJ, Boca S, Freedman ND, et al. Metabolites of tobacco smoking and colorectal cancer risk. Carcinogenesis 2014; 35: 1516 – 22.en_US
dc.identifier.citedreferenceBonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899 – 904.en_US
dc.identifier.citedreferenceBoudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010; 9: 603 – 21.en_US
dc.identifier.citedreferenceCrowe FL, Appleby PN, Travis RC, et al. Circulating fatty acids and prostate cancer risk: individual participant meta‐analysis of prospective studies. J Natl Cancer Inst 2014; 106.en_US
dc.identifier.citedreferencePienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118: 793 – 803.en_US
dc.identifier.citedreferenceEtzioni R, Cha R, Feuer EJ, et al. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998; 148: 775 – 85.en_US
dc.identifier.citedreferenceBrawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012; 30: 195 – 200.en_US
dc.identifier.citedreferenceAl Olama AA, Kote‐Jarai Z, Berndt SI, et al. A meta‐analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46: 1103 – 9.en_US
dc.identifier.citedreferenceNicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008; 455: 1054 – 6.en_US
dc.identifier.citedreferenceO'Connell TM. Recent advances in metabolomics in oncology. Bioanalysis 2012; 4: 431 – 51.en_US
dc.identifier.citedreferenceLokhov PG, Dashtiev MI, Moshkovskii SA, et al. Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics 2010; 6: 156 – 63.en_US
dc.identifier.citedreferenceTrock BJ. Application of metabolomics to prostate cancer. Urol Oncol 2011; 29: 572 – 81.en_US
dc.identifier.citedreferenceMondul AM, Moore SC, Weinstein SJ, et al. 1‐Stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics 2014; 10: 1036 – 41.en_US
dc.identifier.citedreferenceThe ATBC Cancer Prevention Study Group. The alpha‐tocopherol, beta‐carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994; 4: 1 – 10.en_US
dc.identifier.citedreferenceEvans AM, DeHaven CD, Barrett T, et al. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small‐molecule complement of biological systems. Anal Chem 2009; 81: 6656 – 67.en_US
dc.identifier.citedreferenceDehaven CD, Evans AM, Dai H, et al. Organization of gc/ms and lc/ms metabolomics data into chemical libraries. J Cheminform 2010; 2: 9en_US
dc.identifier.citedreferenceSampson JN, Boca SM, Shu XO, et al. Metabolomics in epidemiology: sources of variability in metabolite measurements and implications. Cancer Epidemiol Biomarkers Prev 2013; 22: 631 – 40.en_US
dc.identifier.citedreferenceEfron B, Tibshirani R. On testing the significance of sets of genes. Ann Appl Stat 2006; 1: 107 – 29.en_US
dc.identifier.citedreferenceSubramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge‐based approach for interpreting genome‐wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545 – 50.en_US
dc.identifier.citedreferenceMayers JR, Wu C, Clish CB, et al. Elevation of circulating branched‐chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 2014; 20: 1193 – 8.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ijc29576.pdf
Size:
271.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.